Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine

✍ Scribed by Mar Garcia; Jorge E. Romaguera; Kedar V. Inamdar; George Z. Rassidakis; L. Jeffrey Medeiros

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 393 KB
• Volume: 115
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.24141